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Can pirfenidone prevent paraquat-induced pulmonary ﬁbrosis?dA hypothesisAs you know, paraquat (PQ) poisoning is associated with a high
mortality rate, mainly due to respiratory failure. This herbicide
preferentially accumulates in the lung and its pulmonary effects
are due to the participation of the polyamine transport system
that is mostly expressed in the membrane of alveolar cells types
1 and 2 and Clara cells. The main molecular mechanism of PQ
toxicity is based on redox cycling and intracellular oxidative stress
generation [1–5]. After oxidative destruction, recruitment of the
inﬂammatory cells exacerbates the injury [6]. Based on this mech-
anism, management and research efforts are directed toward the
following: (1) Preventing accumulation of PQ in the lungs (such
as decreasing its absorption and enhancing its elimination from
the blood by forced diuresis and charcoal hemoperfusion); (2) pre-
venting the generation of reactive oxygen species (ROS) by effective
control of iron distribution using desferrioxamine; (3) scavenging
ROS with maintenance of effective levels of antioxidants such as
N-acetylcysteine and vitamin E; (4) repairing ROS- induced lesions
with maintenance of effective levels of glutathione by administra-
tion of N-acetylcysteine; and (5) mainly, reducing acute alveolitis
and pulmonary ﬁbrosis by administration of anti-inﬂammatory
and immunosuppressive drugs such as dexamethasone, methyl-
prednisolone, cyclophosphamide, and N-acetylcysteine or cortico-
steroids in severe cases of toxicity [1,4,7–10]. Based on the
current core concepts of PQ pathogenesis, it can be hypothesized
that pirfenidone (5-methyl-1-phenyl-1H-pyridin-2-one; Pirespa,
Esbriet), which is currently being approved for treatment of idio-
pathic pulmonary ﬁbrosis [11], may prevent PQ-induced pulmo-
nary ﬁbrosis in severe cases of PQ intoxication. In addition to its
antiﬁbrotic properties, pirfenidone has other activities including
anti-inﬂammatory and antihydroxyl radical activities [11]. There-
fore, it seems that this agent theoretically can interrupt the inﬂam-
matory process in the course of PQ toxicity. This hypothesis should
ﬁrst be experimentally tested on animals and if it is shown that pir-
fenidone can prevent the development of PQ-induced pulmonaryConﬂict of interest: none.
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uate the effect of this agent on patients with PQ poisoning.References
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